阅读说明：本技术 来源于根瘤菌种细菌的纳米囊泡及其用途 (Nano-vesicles derived from rhizobium bacteria and uses thereof ) 是由 金润根 于 2019-02-27 设计创作，主要内容包括：本发明涉及来源于根瘤菌属的细菌的囊泡及其用途,并且本发明人已经通过实验证实了在从患有胃癌、结肠癌、乳腺癌、卵巢癌、膀胱癌、前列腺癌、哮喘、糖尿病、帕金森氏病和痴呆症的患者获得的临床样品中的囊泡与正常个体相比显著减少,并且当施用从菌株中分离的囊泡时,由病原囊泡(例如来源于大肠杆菌的囊泡)引起的炎性介质的分泌被显著抑制。因此,期望根据本发明的来源于根瘤菌属的细菌的囊泡可有效地用于诊断胃癌、结肠癌、乳腺癌、卵巢癌、膀胱癌、前列腺癌、哮喘、糖尿病、帕金森氏病或痴呆症的方法以及开发用于预防、减轻或治疗所述疾病的组合物。(The present invention relates to vesicles derived from bacteria of the genus rhizobium and uses thereof, and the present inventors have experimentally confirmed that vesicles in clinical samples obtained from patients with gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, and dementia are significantly reduced compared to normal individuals, and secretion of inflammatory mediators caused by pathogenic vesicles (e.g., vesicles derived from escherichia coli) is significantly inhibited when vesicles isolated from strains are administered. Therefore, it is expected that the vesicles derived from bacteria of the genus rhizobium according to the present invention can be effectively used in a method of diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, or dementia, and in developing a composition for preventing, alleviating, or treating the disease.)

1. A method of providing information useful in diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, or dementia, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the case in which the content of extracellular vesicles derived from a bacterium of the genus Rhizobium is lower than that of the normal individual sample is classified into gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia by quantitative analysis of the PCR product.

2. The method of claim 1, wherein the sample in step (a) is blood or urine.

3. A pharmaceutical composition for preventing or treating one or more diseases selected from the group consisting of gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease and dementia, comprising vesicles derived from the bacterium of the genus rhizobium as an active ingredient.

4. The pharmaceutical composition of claim 3, wherein the average diameter of the vesicles is from 10 to 200 nm.

5. The pharmaceutical composition of claim 3, wherein said vesicles are naturally or artificially secreted from a bacterium of the genus Rhizobium.

6. The pharmaceutical composition of claim 3, wherein the vesicle derived from the bacterium of the genus Rhizobium is a vesicle derived from Rhizobium leguminosarum (Rhizobium leguminatum).

7. A food composition for preventing or alleviating one or more diseases selected from the group consisting of gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease and dementia, comprising vesicles derived from a bacterium of the genus Rhizobium as an active ingredient.

8. The food composition of claim 7, wherein the average diameter of the vesicles is from 10 to 200 nm.

9. The food composition of claim 7, wherein the vesicles are naturally or artificially secreted from the bacteria of the genus Rhizobium.

10. The food composition of claim 7, wherein the vesicles derived from the bacterium of the genus Rhizobium are vesicles derived from Rhizobium leguminosarum (Rhizobium leguminatum).

11. A method of diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, or dementia, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) determining the condition in which the content of extracellular vesicles derived from the bacterium belonging to the genus Rhizobium is lower than that of the sample of the normal individual as stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia by quantitative analysis of the PCR product.

12. A method for preventing or treating one or more diseases selected from the group consisting of stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease and dementia, the method comprising the steps of: administering to the subject a pharmaceutical composition comprising as an active ingredient vesicles derived from a bacterium of the genus rhizobium.

13. Use of vesicles derived from a bacterium of the genus rhizobium for the prevention or treatment of one or more diseases selected from the group consisting of gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease and dementia.

Technical Field

The present invention relates to nanovesicles derived from bacteria of the genus Rhizobium (genus Rhizobium) and uses thereof, and more particularly, to a method of diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, or dementia by using nanovesicles derived from bacteria of the genus Rhizobium, and a composition for preventing, alleviating, or treating the disease comprising the same.

Background

Since the beginning of the 21 st century, acute infectious diseases, which have been considered epidemic in the past, have become less important, and chronic inflammatory diseases accompanied by immune dysfunction due to disharmony between human and microbial communities have changed disease patterns, becoming major diseases that determine quality of life and human longevity. As intractable chronic diseases in the 21 st century, cancer, cardiovascular diseases, chronic pulmonary diseases, metabolic diseases, and neuropsychiatric diseases have become important problems of national public health, and have become major diseases that determine the life span and quality of life of human beings. In particular, these intractable chronic diseases are characterized by chronic inflammation accompanied by abnormal immune function caused by etiology.

As is well known, the number of coexisting microorganisms in the human body has reached 100 trillion, which is 10 times of the number of human cells, and the number of microbial genes is more than 100 times of the number of human genes. A microbiota or group of microorganisms refers to a community of microorganisms, including bacteria, archaea and eukaryotes present in a given habitat.

Bacteria present in our body and bacteria present in the surrounding environment secrete nano-sized vesicles to exchange information about genes, low-molecular compounds, proteins, and the like with other cells. The mucosa forms a physical defense membrane through which particles having a size of 200 nanometers (nm) or more cannot pass, and thus bacteria coexisting in the mucosa cannot pass, but vesicles derived from the bacteria have a size of 100 nm or less and are relatively freely passed through epithelial cells through the mucosa and then absorbed into our body. Vesicles derived from bacteria, which are locally secreted by bacteria, are absorbed through mucosal epithelial cells to cause local inflammatory reactions, while vesicles passing through epithelial cells are absorbed through lymphatic system to be distributed in various organs, and immune and inflammatory reactions are regulated in the organs where the vesicles are distributed. For example, vesicles derived from pathogenic gram-negative bacteria such as escherichia coli locally cause colitis, and when taken up into blood vessels, promote systemic inflammatory reactions and blood coagulation through an intravascular dermatitis reaction, and cause insulin resistance and diabetes when taken up into insulin-acting muscle cells. On the other hand, vesicles derived from beneficial bacteria can control diseases by controlling immune and metabolic dysfunctions caused by pathogenic vesicles.

As an immune response to factors such as bacteria-derived vesicles, a Th17 immune response, which is characterized by secretion of interleukin (hereinafter, IL) -17 cytokines, occurs, and IL-6 is secreted when exposed to bacteria-derived vesicles, thereby inducing a Th17 immune response. Inflammation caused by the Th17 immune response is characterized by neutrophil infiltration, and in the process of inflammation, tumor necrosis factor- α (hereinafter referred to as TNF- α) secreted from inflammatory cells such as macrophages plays an important role.

Rhizobia bacteria are gram-negative bacteria that absorb nitrogen from soil and convert nitrogen in the atmosphere into ammonia while growing in the roots of beans and the like, and then supply nitrogen compounds such as glutamine to plants. However, there has been no report on the extracellular secretion of vesicles by a bacterium of the genus rhizobium, and particularly no report on the use of such a bacterium for the diagnosis and treatment of refractory diseases such as cancer, neurological diseases, or metabolic diseases.

Disclosure of Invention

[ problem ] to provide a method for producing a semiconductor device

As a result of earnest studies to solve the above conventional problems, the inventors confirmed that the content of vesicles derived from bacteria of the genus rhizobium is significantly reduced in samples derived from patients with gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, and dementia as compared to normal individuals through metagenomic analysis, thereby diagnosing diseases. Furthermore, it has been confirmed that when vesicles are isolated from leguminous Rhizobium leguminosarum (Rhizobium leguminosarum) to treat macrophages, IL-6 and TNF- α secretion by pathogenic vesicles is significantly inhibited. Thus, the present invention has been completed.

Accordingly, it is an object of the present invention to provide a method for providing information for diagnosing gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia.

Further, it is another object of the present invention to provide a composition for preventing, alleviating or treating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, which comprises vesicles derived from rhizobia bacteria as an active ingredient.

However, the technical problems to be achieved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned may be clearly understood by those skilled in the art from the following description.

[ technical solution ] A

In order to accomplish the above object of the present invention, the present invention provides a method for providing information for diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) classifying a case in which the content of extracellular vesicles derived from the bacterium of the genus Rhizobium is lower than that of the normal individual sample into gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia by quantitative analysis of the PCR product.

In addition, the present invention provides a method for diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, which comprises the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) determining the condition in which the content of extracellular vesicles derived from the bacterium belonging to the genus Rhizobium is lower than that of the sample of the normal individual as gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia by quantitative analysis of the PCR product.

As an exemplary embodiment of the present invention, the sample in step (a) may be blood or urine.

As another embodiment of the present invention, the pair of primers in step (b) may be primers of SEQ ID No.1 and SEQ ID No. 2.

Further, the present invention provides a pharmaceutical composition for preventing or treating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, comprising vesicles derived from the rhizobium bacterium as an active ingredient.

In addition, the present invention provides a food composition for preventing or alleviating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, comprising vesicles derived from the rhizobium bacterium as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, the method comprising the steps of: administering to the subject a pharmaceutical composition comprising as an active ingredient vesicles derived from a bacterium of the genus rhizobium.

Further, the present invention provides use of the vesicle derived from the bacterium of the genus rhizobium for preventing or treating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia.

In yet another embodiment of the present invention, the average diameter of the vesicles may be 10 to 200 nm.

In another embodiment of the invention, the vesicles may be naturally or artificially secreted from a bacterium of the genus rhizobium.

In another embodiment of the present invention, the vesicle derived from a bacterium of the genus Rhizobium may be a vesicle derived from Rhizobium leguminosarum (Rhizobium leguminosarum).

[ PROBLEMS ] the present invention

The inventors confirmed that intestinal bacteria are not absorbed into the body through epithelial cells, but vesicles derived from the bacteria are absorbed, distributed systemically, and then excreted out of the body through the kidney, liver, and lung, and also confirmed that vesicles derived from rhizobia species bacteria present in clinical samples (e.g., blood or urine) of patients with gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, and dementia are significantly reduced compared to normal individuals by performing metagenomic analysis on vesicles derived from bacteria present in the blood or urine of the patients. In addition, when leguminous rhizobia, which is one of the bacteria of the genus rhizobium, is cultured in vitro to isolate vesicles, and then the vesicles are administered to inflammatory cells in vitro, it was confirmed that secretion of inflammatory mediators mediated by pathogenic vesicles is significantly inhibited. Therefore, it is expected that the vesicles derived from the bacterium belonging to the genus rhizobium according to the present invention can be effectively used in a method for diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, or dementia, and a composition for preventing, alleviating, or treating these diseases.

Drawings

Fig. 1A is a series of photographs of distribution patterns of bacteria and bacteria-derived vesicles (EV) captured by time after oral administration of the bacteria and the bacteria-derived vesicles (EV) to mice, and fig. 1B is a result of evaluating the in vivo distribution patterns of the bacteria and the vesicles by collecting blood, kidneys, liver, and various organs 12 hours after oral administration of the bacteria and the vesicles.

Fig. 2 is a result of comparing the distribution of vesicles derived from rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of gastric cancer patients and normal individuals.

Fig. 3 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of colon cancer patients and normal individuals.

Fig. 4 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of mammary patients and normal individuals.

Fig. 5 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of ovarian cancer patients and normal individuals.

Fig. 6 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of bladder cancer patients and normal individuals.

Fig. 7 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of prostate cancer patients and normal individuals.

Fig. 8 is a result of comparing the distribution of vesicles derived from bacteria of the genus rhizobium after metagenomic analysis of vesicles derived from bacteria present in blood of asthma patients and normal individuals.

Fig. 9 is a result of comparing the distribution of vesicles derived from rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of diabetic patients and normal individuals.

FIG. 10 is a result of comparing the distribution of vesicles derived from bacteria of the genus Rhizobium after metagenomic analysis of vesicles derived from bacteria present in urine of Parkinson's disease patients and normal individuals.

Fig. 11 is a result of comparing the distribution of vesicles derived from rhizobium after metagenomic analysis of vesicles derived from bacteria present in blood of dementia patients and normal individuals.

FIG. 12 is a result of evaluating the effect on the secretion of IL-6 and TNF- α, inflammatory mediators by E.coli EV, by pretreatment of vesicles derived from bacteria of the genus Rhizobium, prior to treatment of pathogenic vesicles such as E.coli EV, to evaluate the anti-inflammatory and immunomodulatory effects of vesicles derived from leguminous Rhizobium (NC: negative control; PC: positive control, E.coli EV 1. mu.g/ml; LP-1.0: Lactobacillus plantarum EV 1.0. mu.g/ml; RL-0.1, 1.0, 10: leguminous Rhizobium EV 0.1, 1.0, 10. mu.g/ml).

Detailed Description

The present invention relates to vesicles derived from bacteria of the genus rhizobium and uses thereof.

The inventors confirmed through metagenomic analysis that vesicles derived from bacteria of the genus rhizobium are significantly reduced in clinical samples obtained from patients with gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, and dementia, as compared to normal individuals, thereby diagnosing diseases. In addition, by isolating vesicles from leguminous rhizobia and analyzing the properties thereof, it was confirmed that the vesicles can be used in a composition for preventing, alleviating or treating diseases such as stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia.

Accordingly, the present invention provides a method for providing information for diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) determining the condition in which the content of extracellular vesicles derived from the bacterium belonging to the genus Rhizobium is lower than that of the sample of the normal individual as gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia by quantitative analysis of the PCR product.

As used herein, the term "diagnosis" refers to the determination of a disease condition of a patient in a broad sense and in all aspects. The determination is made as to the entity, cause, pathogenesis, severity, detailed aspect of the disease, presence or absence of complications, prognosis, etc. of the disease. The diagnosis in the present invention refers to determining whether or not gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease and/or dementia occur, the degree of the disease, and the like.

As used herein, the term "nanovesicle" or "vesicle" refers to a structure composed of nano-sized membranes secreted from various bacteria. Vesicles or Outer Membrane Vesicles (OMVs) derived from gram-negative bacteria have endotoxins (lipopolysaccharides), toxic proteins, bacterial DNA and RNA, and vesicles derived from gram-positive bacteria have peptidoglycans and lipoteichoic acids, which are cell wall components of the bacteria, in addition to proteins and nucleic acids. In the present invention, the nanovesicles or vesicles are naturally secreted or artificially produced by bacteria of the genus rhizobium, have a spherical shape, and have an average diameter of 10 to 200 nm.

As used herein, the term "metagenome" also refers to microbiome, and refers to the entire genome including all viruses, bacteria, fungi, etc., in independent areas such as soil and animal intestines, and is generally used as a concept of genome explaining analysis of uncultured microorganisms by identifying a large number of microorganisms at a time using a sequence analyzer. In particular, metagenome does not refer to the genome of one species, but refers to a mixed genome, the genome of all species as one environmental unit. When a species is defined in the course of the development of omics biology, the metagenome is a term derived from the point of view of forming the complete species, which is formed by various species interacting with each other as well as a functionally present species. Technically, metagenome is the target of technology that identifies all species in one environment by rapid sequence analysis methods, by analyzing all DNA and RNA regardless of the species, and studies interactions and metabolism.

In the present invention, the sample may be blood or urine, but is not limited thereto.

As another aspect of the present invention, there is provided a composition for preventing, treating or alleviating gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease or dementia, comprising vesicles derived from the rhizobium bacterium as an active ingredient. The composition includes a food composition and a pharmaceutical composition, and in the present invention, the food composition includes a health functional food composition. The compositions of the present invention may be oral sprays or inhalants.

As used herein, the term "prevention" refers to all actions of inhibiting gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, dementia and/or the like or delaying the onset thereof by administering a composition according to the present invention.

As used herein, the term "treatment" refers to the alleviation or beneficial alteration of all behaviors of the symptoms of gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, dementia and/or similar diseases by administration of a composition according to the invention.

As used herein, the term "alleviating" refers to all actions that at least reduce a parameter (e.g., the extent of symptoms) associated with the condition being treated.

Vesicles can be isolated from a culture solution comprising rhizobia bacteria by using one or more methods selected from centrifugation, ultracentrifugation, high pressure processing, extrusion, sonication, cell lysis, homogenization, freeze-thaw, electroporation, mechanical disintegration, chemical processing, filtration through a filter, gel filtration chromatography, free-flow electrophoresis, and capillary electrophoresis. In addition, processes such as washing for removing impurities and concentration of the obtained vesicles may be further included.

The pharmaceutical compositions of the present invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are generally used in the formulation, and include, but are not limited to, physiological saline (saline), sterile water, ringer's solution, buffered saline, cyclodextrin, glucose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like, and may further include other typical additives such as antioxidants and buffers, if necessary. In addition, the composition may be formulated into injectable preparations such as aqueous solutions, suspensions and emulsions, pills, capsules, granules or tablets by additionally adding diluents, dispersants, surfactants, binders, lubricants and the like. With respect to suitable pharmaceutically acceptable carriers and formulations, the compositions can be formulated according to each ingredient, preferably by using the method disclosed in Remington's medicament (the ramington literature). The formulation of the pharmaceutical composition of the present invention is not particularly limited, but may be formulated into injections, inhalants, external preparations for skin, oral preparations, and the like.

The pharmaceutical composition of the present invention may be orally administered or parenterally administered (e.g., intravenous, subcutaneous, intradermal, intranasal or intratracheal administration) according to a desired method, and the dosage may vary according to the condition and body weight of a patient, the severity of a disease, a pharmaceutical preparation, and the administration route and duration, but may be appropriately selected by one of ordinary skill in the art.

The pharmaceutical composition according to the invention is administered in a pharmaceutically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and an effective dosage level may be determined depending on factors including the type of disease of a patient, the severity of the disease, pharmaceutical activity, sensitivity to a drug, administration time, administration route, excretion rate, treatment period, and concurrent use of a drug, and other factors well known in the medical field. The composition according to the present invention may be administered as a therapeutic agent alone or in combination with other therapeutic agents, may be administered sequentially or simultaneously with the therapeutic agents in the related art, and may be administered in a single dose or multiple doses. In view of all the above factors, it is important to administer the composition in the minimum amount that can achieve the maximum effect without any side effects, which can be readily determined by one of ordinary skill in the art.

Specifically, the effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex and body weight of a patient, and is usually 0.001 to 150mg of the composition per 1 kg of body weight, preferably 0.01 to 100mg per 1 kg of body weight, and may be administered daily or every other day, or once to three times daily. However, the above dose is not intended to limit the scope of the present invention in any way, since the dose may be increased or decreased depending on the administration route, severity of obesity, sex, body weight or age.

The food composition of the present invention includes a health functional food composition. The food composition according to the present invention may be used by adding the active ingredient to food as it is, or may be used together with other food or food ingredients, but may be used as appropriate according to typical methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of its use (for prevention or alleviation). Generally, when preparing a food or beverage, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw materials. However, for long-term intake for health and hygiene purposes or for health control purposes, the amount may be less than the above range.

Other ingredients are not particularly limited except that the food composition of the present invention contains the active ingredient in a designated ratio as an essential ingredient, and the food composition of the present invention may contain various flavors, natural carbohydrates, etc. as additional ingredients, as in a typical beverage. Examples of the above natural carbohydrates include conventional sugars such as monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, and the like; and polysaccharides such as dextrin, cyclodextrin and the like; and sugar alcohols such as xylitol, sorbitol and erythritol. As a flavoring agent other than the above-described flavoring agents, natural flavoring agents (thaumatin, stevia extracts such as rebaudioside a, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.

In addition to the additives, the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents (e.g., synthetic flavoring agents and natural flavoring agents), coloring agents and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. These ingredients may be used alone or in combination thereof. The proportion of these additives may also be appropriately selected by those of ordinary skill in the art.

In one embodiment of the present invention, by orally administering bacteria and vesicles derived from bacteria to mice and observing the in vivo absorption, distribution and excretion patterns of the bacteria and vesicles, it was confirmed that, although bacteria are not absorbed through the intestinal mucosa, the vesicles derived from bacteria are absorbed and distributed systemically within 5 minutes after administration and are excreted through the kidney, liver, and the like (see example 1).

In another embodiment of the present invention, the bacterial metagenomic analysis is performed by using vesicles isolated from blood or urine of normal individuals whose age and sex are matched with patients suffering from gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease and dementia. The results confirmed that vesicles derived from bacteria of the genus rhizobium were significantly reduced in clinical samples of patients with gastric cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, parkinson's disease, and dementia, compared to samples of normal individuals (see examples 3 to 12).

In another embodiment of the present invention, leguminous rhizobia was cultured to evaluate whether vesicles secreted therefrom have immunomodulatory and anti-inflammatory effects, and by evaluating secretion of inflammatory mediators via treatment of escherichia coli (e.coli EV) as a pathogenic factor of inflammatory diseases after treating macrophages with vesicles derived from leguminous rhizobia at various concentrations, it was confirmed that secretion of IL-6 and TNF- α by escherichia coli vesicles (e.coli EV) was effectively inhibited by vesicles derived from leguminous rhizobia (see example 13).

Hereinafter, preferred embodiments will be presented to aid in understanding the present invention. However, the following examples are provided only for easier understanding of the present invention, and the contents of the present invention are not limited by the following examples.